Imagine a cancer therapy as unique as a fingerprint. A Hyderabad-based startup is at the forefront of this medical revolution, developing vaccines engineered to fight a patient's specific tumour, one person at a time.
A New Frontier in Cancer Treatment
For decades, cancer treatment has
largely relied on a three-pronged approach: surgery, radiation, and chemotherapy. While effective, these methods can be a blunt instrument, often damaging healthy cells alongside cancerous ones. The next frontier in oncology is far more precise. It involves creating treatments tailored to the unique genetic signature of an individual's tumour. This is the world of personalised cancer vaccines, a groundbreaking approach that aims to teach a patient's own immune system how to identify and destroy cancer cells with remarkable accuracy. Unlike traditional vaccines that prevent infectious diseases, these are therapeutic, designed to treat an existing cancer by targeting its specific markers.
The Science of 'Self' vs 'Other'
The core concept behind personalised cancer vaccines lies in 'neoantigens'. Cancer cells have genetic mutations that healthy cells do not possess. These mutations can cause the cancer cells to produce abnormal proteins, which act as unique flags, or neoantigens, on their surface. Because these markers are exclusive to the tumour, they provide a perfect target for the immune system. The process begins by taking a sample of a patient's tumour and sequencing its DNA to identify these unique mutations. Using sophisticated tools, scientists select the most promising neoantigens that are likely to trigger a strong immune response. This information then serves as the blueprint for creating a custom vaccine for that single patient.
Enter PopVax: A Hyderabad Pioneer
At the heart of this innovation in India is PopVax, a biotechnology startup in Hyderabad founded in 2021 by Soham Sankaran. The company is harnessing a powerful combination of artificial intelligence (AI), machine learning, and messenger RNA (mRNA) technology to drive its personalised vaccine programme. PopVax uses AI to analyse the genetic data from a tumour and predict which neoantigens will be most effective at stimulating the immune system. The chosen targets are then encoded into an mRNA vaccine, the same flexible technology that gained prominence during the COVID-19 pandemic. The mRNA acts like a 'wanted poster', delivering instructions to the body's cells to produce the specific tumour neoantigens, thereby training the immune system to recognise and hunt down the cancer.
The 'RNA Foundry' and the Path Forward
To accelerate its work, PopVax recently launched the 'RNA Foundry' in Hyderabad, an integrated facility for research, development, and manufacturing of these personalised medicines. This allows the company to manage the entire complex process inhouse, from AIdriven design to producing the final vaccine. The company has stated its goal is to produce over 100 patientspecific vaccines in the coming year. However, the road ahead involves significant challenges. The process is resourceintensive and timeconsuming, a critical factor when dealing with aggressive cancers. While PopVaxs broader vaccine platform has entered clinical trials for other diseases, its personalised cancer vaccines are still in early stages and will require their own trials to prove safety and efficacy. These vaccines are intended to be used alongside other treatments, like checkpoint inhibitors, to create a more powerful and coordinated attack against the cancer.
